文献速递糖尿病

2型糖尿病二线治疗:心血管与肾脏共病中的治疗/获益悖论

Second-Line Therapy for Type 2 Diabetes Management: The Treatment/Benefit Paradox of Cardiovascular and Kidney Comorbidities.
PubMed 文献 · Diabetes Care · 2021-01-01

该回顾性队列研究分析2016-2019年OptumLabs数据库中起始GLP-1RA、SGLT2i或DPP-4i的成人2型糖尿病患者,发现合并心梗、脑血管病、心衰或肾病者反而更少起始有获益证据的GLP-1RA或SGLT2i,非白人和老年患者中此悖论更显著。

要点

  • 合并心梗、脑血管病或肾病者起始GLP-1RA的RRR分别为0.83、0.77、0.87(对比DPP-4i)。
  • 合并心衰或肾病者起始SGLT2i的RRR分别为0.83和0.57(对比DPP-4i)。
  • 非白人和老年患者更少起始GLP-1RA或SGLT2i。

核心结论

  • 有心血管病、心衰和肾病的患者本应更可能从GLP-1RA和/或SGLT2i获益,却更少起始这些药物。
  • 治疗/获益悖论在非白人和老年患者中最为突出,解决该悖论可能有助于减少相关疾病负担。

研究设计与样本

  • 回顾性分析OptumLabs数据仓库中商业保险和Medicare Advantage受益人的索赔数据。
  • 纳入2016至2019年间首次起始GLP-1RA、SGLT2i或DPP-4i的成人2型糖尿病患者。
  • 采用多项逻辑回归调整人口学和其它临床因素后计算相对风险比(RRR)。
  • 共识别75,395例起始GLP-1RA、58,234例起始SGLT2i、91,884例起始DPP-4i的患者。

主要发现

  • 有心肌梗死史者起始GLP-1RA而非DPP-4i的RRR为0.83(95%CI 0.78-0.88)。
  • 有脑血管病者起始GLP-1RA而非DPP-4i的RRR为0.77(95%CI 0.74-0.81)。
  • 有肾病者起始GLP-1RA而非DPP-4i的RRR为0.87(95%CI 0.84-0.91)。
  • 有心衰者起始SGLT2i的RRR为0.83(95%CI 0.80-0.87),有肾病者为0.57(95%CI 0.55-0.60)。
  • 非白人和老年患者更少起始GLP-1RA和SGLT2i。

临床怎么用

  • 对合并心血管病、心衰或肾病的2型糖尿病患者,应优先考虑有证据支持的GLP-1RA或SGLT2i。
  • 关注非白人和老年患者中治疗/获益悖论,促进公平处方。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine whether glucagon-like peptide 1 receptor agonists (GLP-1RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) are preferentially initiated among patients with cardiovascular disease, heart failure (HF), or nephropathy, where these drug classes have established benefit, compared with dipeptidyl peptidase 4 inhibitors (DPP-4i), for which corresponding benefits have not been demonstrated. RESEARCH DESIGN AND METHODS: We retrospectively analyzed claims of adults with type 2 diabetes included in OptumLabs Data Warehouse, a deidentified database of commercially insured and Medicare Advantage beneficiaries, who first started GLP-1RA, SGLT2i, or DPP-4i therapy between 2016 and 2019. Using multinomial logistic regression, we examined the relative risk ratios (RRR) of starting GLP-1RA and SGLT2i compared with DPP-4i for those with a history of myocardial infarction (MI), cerebrovascular disease, HF, and nephropathy after adjusting for demographic and other clinical factors. RESULTS: We identified 75,395 patients who started GLP-1RA, 58,234 who started SGLT2i, and 91,884 who started DPP-4i. Patients with prior MI, cerebrovascular disease, or nephropathy were less likely to start GLP-1RA rather than DPP-4i compared with patients without these conditions (RRR 0.83 [95% CI 0.78-0.88] for MI, RRR 0.77 [0.74-0.81] for cerebrovascular disease, and RRR 0.87 [0.84-0.91] for nephropathy). Patients with HF or nephropathy were less likely to start SGLT2i (RRR 0.83 [0.80-0.87] for HF and RRR 0.57 [0.55-0.60] for nephropathy). Both medication classes were less likely to be started by non-White and older patients. CONCLUSIONS: Patients with cardiovascular disease, HF, and nephropathy, for whom evidence suggests a greater likelihood of benefiting from GLP-1RA and/or SGLT2i therapy, were less likely to start these drugs. Addressing this treatment/benefit paradox, which was most pronounced in non-White and older patients, may help reduce the morbidity associated with these conditions.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. McCoy RG, Van Houten HK, Karaca-Mandic P, et al. Second-Line Therapy for Type 2 Diabetes Management: The Treatment/Benefit Paradox of Cardiovascular and Kidney Comorbidities. Diabetes Care. 2021. PMID: 34348996. doi:10.2337/dc20-2977

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。